Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Ipilimumab 3 mg/kg was the first agent to improve survival of pretreated advanced melanoma patients. Nonconventional response patterns to ipilimumab have been reported widely, but most of these data were from studies with ipilimumab 10 mg/kg. Here, case reports from five patients treated within an expanded access program (EAP) with ipilimumab at its licensed dose of 3 mg/kg illustrate the efficacy of ipilimumab in an expanded access setting and the range of different tumor response patterns encountered. The durable clinical benefit seen in these patients despite the observed atypical response patterns highlights the necessity for comprehensive clinical decision making.
Original languageEnglish
Pages (from-to)712-720
Number of pages9
JournalCancer Invest.
Volume30
Issue numberCancer Invest. 2012 Dec;30(10):712-20. doi: 10.310
Publication statusPublished - 2012

Keywords

  • Solid Tumors

Fingerprint Dive into the research topics of 'Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports'. Together they form a unique fingerprint.

Cite this